Methotrexate Market Size, Share, Growth, and Industry Analysis, By Type (Methotrexate for Injection,Methotrexate Tablets), By Application (Used for Cancers,Used for Rheumatoid Arthritis,Used for Other Diseases), Regional Insights and Forecast to 2035

Methotrexate Market Overview

The global Methotrexate Market is forecast to expand from USD 631.76 million in 2026 to USD 653.93 million in 2027, and is expected to reach USD 862.05 million by 2035, growing at a CAGR of 3.51% over the forecast period.

The global methotrexate market is experiencing steady expansion, with over 185 million treatment doses administered annually across oncology, autoimmune, and dermatology sectors. Methotrexate use in oncology accounts for 42% of global prescriptions, targeting malignancies like leukemia, breast cancer, and osteosarcoma. Autoimmune diseases represent 38% of usage, with rheumatoid arthritis being the leading indication, impacting over 23 million patients worldwide. Dermatology applications, including psoriasis treatment, comprise 14% of market demand. Over 71% of global supply comes from large-scale pharmaceutical producers with established manufacturing facilities meeting WHO GMP standards, while 29% comes from regional and specialty drug manufacturers serving localized markets.

The United States accounts for 32% of the global methotrexate market, with over 59 million treatment doses dispensed annually. Oncology use represents 45% of national demand, followed by rheumatoid arthritis at 37% and psoriasis at 11%. The US healthcare system supports more than 1,800 oncology treatment centers and 2,600 rheumatology clinics that administer methotrexate regularly. Approximately 68% of methotrexate prescriptions are fulfilled through hospital pharmacies, while 32% are processed via retail and specialty pharmacies. Domestic manufacturing fulfills 54% of demand, with the remainder sourced from international suppliers through FDA-approved imports.

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

Key Findings

• Key Market Driver: 67% of global methotrexate prescriptions are linked to rising cancer and autoimmune disease prevalence.
• Major Market Restraint: 41% of healthcare providers cite supply chain disruptions as a key challenge.
• Emerging Trends: 52% increase in subcutaneous methotrexate formulations for self-administration.
• Regional Leadership: North America holds 38% of global unit sales, followed by Asia-Pacific at 31% and Europe at 25%.
• Competitive Landscape: Top five global manufacturers account for 56% of total supply volumes.
• Market Segmentation: Methotrexate for injection represents 61% of demand, while tablets account for 39%.
• Recent Development: 48% of new production capacity in 2024 is located in Asia-Pacific facilities.

Methotrexate Market Latest Trends

Recent trends in the methotrexate market show a shift toward patient-centric delivery formats, with subcutaneous auto-injectors growing by 52% in adoption since 2021. Hospital oncology departments have increased the use of high-dose methotrexate protocols, now accounting for 27% of all oncology-related administrations. Combination therapies are on the rise, with methotrexate being paired in 34% of rheumatoid arthritis regimens to enhance treatment outcomes. Generic methotrexate production now covers 76% of the total market, reducing patient costs and expanding access in low-income regions. In Asia-Pacific, production facilities have increased output by 18% year-on-year to meet local demand. Safety and efficacy monitoring systems have improved, with 62% of global healthcare providers using electronic tracking to monitor patient outcomes and adverse events in methotrexate treatment.

Methotrexate Market Dynamics

DRIVER

"Growing incidence of autoimmune diseases and cancers."

In 2024, rheumatoid arthritis affected over 23 million individuals globally, while cancer incidence exceeded 19 million new cases. Methotrexate remains a primary therapeutic choice in 41% of chemotherapy regimens for leukemia and in 68% of rheumatoid arthritis treatment protocols, driving consistent market demand.

RESTRAINT

"Supply chain vulnerabilities impacting global distribution."

41% of healthcare systems reported delays in methotrexate shipments during 2023–2024 due to raw material shortages and logistical disruptions. Manufacturing dependencies on limited active pharmaceutical ingredient (API) suppliers have created bottlenecks, especially in North America and parts of Europe.

OPPORTUNITY

"Expansion of biosimilar and generic methotrexate production."

Generic formulations now represent 76% of total global methotrexate usage, with over 28 new manufacturing licenses issued since 2021. Lower production costs in Asia-Pacific enable broader access, particularly in emerging economies with growing healthcare investments.

CHALLENGE

"Adverse event management and toxicity control."

Approximately 19% of methotrexate patients experience moderate to severe side effects requiring medical intervention. High-dose toxicity management adds treatment costs and creates reluctance among physicians to initiate methotrexate therapy in borderline clinical cases.

Methotrexate Market Segmentation

The methotrexate market is segmented by type and application to address diverse medical needs.

Get Comprehensive Insights on the Market Segmentation in this Report

Download FREE Sample

BY TYPE

Methotrexate for Injection: Accounts for 61% of global demand, with over 113 million doses administered annually. Preferred in oncology for high-dose regimens, particularly in treating acute lymphoblastic leukemia and osteosarcoma.

Methotrexate for injection is valued at USD 372.29 million in 2025, representing 61% of the global market, and is projected to expand at a CAGR of 3.58% to 2034, driven by oncology and hospital-administered autoimmune treatments.

Top 5 Major Dominant Countries in the Methotrexate for Injection Segment

• United States: USD 111.68 million, 30% share, 3.6% CAGR; high hospital-based oncology adoption and consistent use in acute lymphoblastic leukemia treatment protocols.
• China: USD 78.18 million, 21% share, 3.7% CAGR; driven by government-subsidized cancer programs and increasing rheumatoid arthritis patient base.
• Germany: USD 48.40 million, 13% share, 3.6% CAGR; strong usage in hospital oncology units and public-funded cancer care programs.
• Japan: USD 41.05 million, 11% share, 3.5% CAGR; usage led by oncology and combination therapies for autoimmune diseases.
• India: USD 37.23 million, 10% share, 3.7% CAGR; rapid expansion of oncology facilities and rising autoimmune diagnosis rates.

Methotrexate Tablets: Represent 39% of the market, with around 72 million annual prescriptions. Commonly prescribed for long-term rheumatoid arthritis management and dermatology cases requiring consistent low-dose administration.

Methotrexate tablets are valued at USD 238.04 million in 2025, holding 39% of the global market, and are expected to grow at a CAGR of 3.41% to 2034, mainly for long-term autoimmune disease management.

Top 5 Major Dominant Countries in the Methotrexate Tablets Segment

• United States: USD 71.41 million, 30% share, 3.4% CAGR; widely prescribed for chronic rheumatoid arthritis management in outpatient settings.
• China: USD 54.74 million, 23% share, 3.5% CAGR; expanding prescription base in primary healthcare centers and specialty clinics.
• Japan: USD 35.71 million, 15% share, 3.4% CAGR; high uptake in low-dose regimens for autoimmune patients.
• Germany: USD 28.56 million, 12% share, 3.4% CAGR; prescription rates rising in rheumatology and dermatology departments.
• India: USD 21.42 million, 9% share, 3.5% CAGR; strong penetration in generics market with cost-efficient supply.

BY APPLICATION

Used for Cancers: Represents 42% of methotrexate demand, covering over 78 million annual doses across leukemia, breast cancer, and lymphoma treatments.

Methotrexate used for cancers is valued at USD 256.33 million in 2025, holding 42% share, with a CAGR of 3.55%, covering leukemia, breast cancer, and osteosarcoma treatments.

Top 5 Major Dominant Countries in the Used for Cancers Application

• United States: USD 76.90 million, 30% share, 3.6% CAGR; strong hospital oncology infrastructure and adoption in over 1,800 cancer centers.
• China: USD 61.52 million, 24% share, 3.7% CAGR; increased availability in state-funded oncology programs.
• Germany: USD 35.88 million, 14% share, 3.6% CAGR; usage driven by advanced chemotherapy regimens.
• Japan: USD 30.76 million, 12% share, 3.5% CAGR; focused on multi-drug oncology protocols.
• India: USD 25.63 million, 10% share, 3.7% CAGR; rising cancer patient load in urban healthcare centers.

Used for Rheumatoid Arthritis: Accounts for 38% of global consumption, with around 71 million annual prescriptions.

Methotrexate for rheumatoid arthritis is valued at USD 231.92 million in 2025, accounting for 38% share, with a CAGR of 3.48%, serving as the first-line DMARD in most treatment guidelines.

Top 5 Major Dominant Countries in the Used for Rheumatoid Arthritis Application

• United States: USD 69.58 million, 30% share, 3.5% CAGR; high prevalence rates with 1.3 million diagnosed cases.
• China: USD 55.66 million, 24% share, 3.6% CAGR; increasing access in public hospitals and rural clinics.
• Japan: USD 32.47 million, 14% share, 3.5% CAGR; strong rheumatology department adoption in urban hospitals.
• Germany: USD 27.83 million, 12% share, 3.4% CAGR; used in combination with biologics for enhanced efficacy.
• India: USD 20.87 million, 9% share, 3.6% CAGR; expansion of rheumatology care across secondary healthcare centers.

Used for Other Diseases: Covers 20% of demand, including psoriasis and ectopic pregnancy treatments, totaling 37 million doses annually.

Methotrexate used for other diseases is valued at USD 122.08 million in 2025, representing 20% share, with a CAGR of 3.42%, applied in psoriasis, ectopic pregnancy, and certain inflammatory disorders.

Top 5 Major Dominant Countries in the Used for Other Diseases Application

• United States: USD 36.62 million, 30% share, 3.4% CAGR; psoriasis management accounts for 40% of this category’s usage.
• China: USD 29.30 million, 24% share, 3.5% CAGR; growing use in gynecological treatments and dermatology.
• Japan: USD 18.31 million, 15% share, 3.4% CAGR; expansion in dermatology clinics for chronic skin conditions.
• Germany: USD 14.65 million, 12% share, 3.4% CAGR; consistent use in dermatology and non-oncology autoimmune treatments.
• India: USD 10.97 million, 9% share, 3.5% CAGR; strong application in skin disorder treatments across private clinics.

Methotrexate Market Regional Outlook

Get Comprehensive Insights into the Market’s Size and Growth Trends

Download FREE Sample

North America

North America holds 38% of the global methotrexate market, translating to approximately 70 million annual treatment doses across oncology, autoimmune, and dermatology applications. The United States accounts for 84% of regional usage, equaling around 58.8 million doses annually, driven by high prevalence rates of rheumatoid arthritis and a robust oncology treatment infrastructure with over 1,800 cancer centers.

North America’s methotrexate market is valued at USD 231.92 million in 2025, holding 38% global share, with a CAGR of 3.52%, led by oncology and autoimmune disease management in the United States and Canada.

North America - Major Dominant Countries in the Methotrexate Market

• United States: USD 194.81 million, 84% share, 3.5% CAGR; dominant in oncology, RA, and dermatology with large hospital and clinic networks.
• Canada: USD 27.83 million, 12% share, 3.5% CAGR; strong public healthcare coverage for methotrexate-based treatments.
• Mexico: USD 9.28 million, 4% share, 3.6% CAGR; growing hospital oncology infrastructure.
• Puerto Rico: USD 0.92 million, 0.4% share, 3.4% CAGR; niche demand in dermatology.
• Bahamas: USD 0.46 million, 0.2% share, 3.4% CAGR; limited but stable hospital-based usage.

Europe

Europe accounts for 25% of global methotrexate consumption, totaling around 46 million doses annually. Germany leads with 22% of European demand, or about 10.1 million doses, driven by large-scale public hospital systems and active participation in oncology clinical trials. The United Kingdom follows with 19%, or 8.7 million doses, with high methotrexate penetration in both NHS and private healthcare settings for RA and psoriasis.

Europe is valued at USD 152.58 million in 2025, accounting for 25% global share, with a CAGR of 3.49%, supported by biosimilar adoption and strong oncology care systems.

Europe - Major Dominant Countries in the Methotrexate Market

• Germany: USD 33.57 million, 22% share, 3.5% CAGR; high use in oncology and RA protocols.
• United Kingdom: USD 28.99 million, 19% share, 3.5% CAGR; extensive NHS funding for methotrexate treatments.
• France: USD 24.41 million, 16% share, 3.4% CAGR; oncology-focused adoption in major hospitals.
• Italy: USD 21.36 million, 14% share, 3.4% CAGR; balanced use across oncology and dermatology.
• Spain: USD 16.78 million, 11% share, 3.4% CAGR; RA and psoriasis are key usage drivers.

Asia-Pacific

Asia-Pacific holds 31% of global methotrexate demand, equivalent to approximately 57 million annual doses. China dominates with 36% of the region’s usage, or about 20.52 million doses, led by a surge in rheumatoid arthritis diagnoses and government-backed oncology programs. India follows with 28% share, totaling 15.96 million doses, supported by one of the world’s largest generics manufacturing sectors and expanding rural healthcare outreach.

Asia’s methotrexate market is valued at USD 189.20 million in 2025, representing 31% global share, with a CAGR of 3.54%, driven by large patient pools and expanding access to generics.

Asia - Major Dominant Countries in the Methotrexate Market

• China: USD 68.11 million, 36% share, 3.6% CAGR; strong growth in oncology and RA usage.
• India: USD 53.38 million, 28% share, 3.6% CAGR; high demand from generic supply chains.
• Japan: USD 34.06 million, 18% share, 3.5% CAGR; widespread use in autoimmune diseases.
• South Korea: USD 17.03 million, 9% share, 3.5% CAGR; growing hospital-based prescription rates.
• Australia: USD 11.35 million, 6% share, 3.4% CAGR; strong RA and dermatology adoption.

Middle East & Africa

The Middle East & Africa region represents 6% of the global methotrexate market, equating to approximately 11 million annual doses. South Africa leads with 28% of regional usage, or about 3.08 million doses, supported by expanding oncology and autoimmune treatment programs in public hospitals. Saudi Arabia holds 24%, or 2.64 million doses, with substantial demand from tertiary care centers and specialized RA clinics.

Middle East & Africa are valued at USD 36.62 million in 2025, holding 6% global share, with a CAGR of 3.43%, led by hospital-based oncology and autoimmune care.

Middle East and Africa - Major Dominant Countries in the Methotrexate Market

• South Africa: USD 10.25 million, 28% share, 3.4% CAGR; public healthcare drives RA and oncology demand.
• Saudi Arabia: USD 8.79 million, 24% share, 3.4% CAGR; strong tertiary care infrastructure.
• Egypt: USD 6.59 million, 18% share, 3.4% CAGR; oncology and dermatology lead usage.
• Nigeria: USD 5.49 million, 15% share, 3.5% CAGR; expanding oncology centers in urban areas.
• UAE: USD 4.50 million, 11% share, 3.4% CAGR; medical tourism and private sector demand.

List of Top Methotrexate Companies

• Huiyu
• Teva Pharmaceutical Industries
• Powerdone
• Maoxiang
• Roxane Laboratories
• Pfizer (Hospira)
• LingNan Pharmaceutical
• Sine
• Qualitestrx (DAVA Pharmaceuticals)

Top Two Companies With Highest Share

• Teva Pharmaceutical Industries holds 17% of the global market, supplying over 31 million doses annually. Pfizer (Hospira) follows with 13% share, producing around 24 million doses across oncology and autoimmune indications.

Investment Analysis and Opportunities

Since 2021, over USD 2.1 billion has been invested globally in expanding methotrexate manufacturing capacity. Asia-Pacific accounts for 44% of this investment, primarily in India and China, where new plants are increasing API production. In North America, public–private partnerships have invested in securing domestic manufacturing to reduce reliance on imports. More than 30 new production facilities are scheduled for completion by 2028, with a combined output potential of 105 million additional doses annually. Opportunities also exist in self-injectable and patient-friendly delivery systems, which are projected to increase their market share by 15% over the next five years.

New Product Development

In 2024, 38% of newly launched methotrexate products were subcutaneous formulations with enhanced patient usability. Auto-injectors with pre-filled dosing have gained traction in rheumatoid arthritis management, now available in over 50 countries. Long-acting methotrexate formulations are in clinical trials, aiming to reduce dosing frequency from weekly to biweekly or monthly. Novel combination therapies pairing methotrexate with biologics have shown 27% higher efficacy rates in autoimmune patients compared to monotherapy. Advanced manufacturing processes have improved batch consistency, reducing impurity rates by 12% in high-dose injectable products.

Five Recent Developments

• Teva expanded production in India, adding 15 million annual dose capacity.
• Pfizer (Hospira) launched a new pre-filled syringe line for RA patients.
• Huiyu gained regulatory approval for methotrexate auto-injectors in Southeast Asia.
• Roxane Laboratories initiated trials for long-acting injectable methotrexate.
• Maoxiang upgraded manufacturing lines to meet new global GMP standards.

Report Coverage of Methotrexate Market

The Methotrexate Market Report provides a comprehensive assessment of market volume, segmentation, regional distribution, and key manufacturers. It covers more than 250 data points, including dosage volume trends, therapeutic area shares, and manufacturing capacities. The analysis examines oncology, autoimmune, and dermatology segments, along with product type performance between injectables and oral tablets. The report also evaluates regional consumption patterns across 40 countries, mapping supply chains from API production to finished dosage form distribution. Competitive benchmarking of leading producers is included, along with tracking of regulatory approvals, investment pipelines, and product innovation initiatives shaping the methotrexate industry outlook through 2034.

Methotrexate Market Report Coverage

REPORT COVERAGE	DETAILS
Market Size Value In	USD 631.76 Million in 2026
Market Size Value By	USD 862.05 Million by 2035
Growth Rate	CAGR of 3.51% from 2026-2035
Forecast Period	2026 - 2035
Base Year	2025
Historical Data Available	Yes
Regional Scope	Global
Segments Covered	By Type : Methotrexate for Injection Methotrexate Tablets By Application : Used for Cancers Used for Rheumatoid Arthritis Used for Other Diseases
To Understand the Detailed Market Report Scope & Segmentation Download FREE Sample